London, June 23, 2020 – Further to the announcements by Hikma and Boehringer Ingelheim Invest GmbH (“Boehringer Ingelheim”) on 22nd June 2020, Hikma Pharmaceuticals PLC (“Hikma” or the “Company”) today announces the Company has entered into arrangements to buy back approximately 12.8 million ordinary shares (the “Buy Back Shares”) currently owned by Boehringer Ingelheim (the “Buy Back”) at a price per Buy Back Share of £23.00 (the “Buy Back Price”). Hikma will receive a commitment fee from Boehringer Ingelheim of 2 per cent. of the aggregate value of the Buy Back Shares acquired at the Buy Back Price. Citigroup Global Markets Limited (“Citi”) is acting as riskless principal for the purpose of the Buy Back.
23 June 2020
Corporate, Press Release
The Buy Back Shares will all be held as treasury shares. Following the Buy Back, the Company's share capital consists of 243,283,072 ordinary shares carrying voting rights, of which 12,833,233 (5.3%) ordinary shares are held in treasury. The voting rights attaching to the treasury shares are not capable of exercise. Therefore the total number of the voting rights in the Company (after excluding the treasury shares) is 230,449,839 (“Total Voting Rights”).
The Total Voting Rights figure (230,449,839) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
Citi and Goldman Sachs International (“Goldman Sachs”) are acting as joint financial advisers to Hikma on the Buy Back.